astragaloside a has been researched along with benazepril in 1 studies
| Studies (astragaloside a) | Trials (astragaloside a) | Recent Studies (post-2010) (astragaloside a) | Studies (benazepril) | Trials (benazepril) | Recent Studies (post-2010) (benazepril) |
|---|---|---|---|---|---|
| 675 | 5 | 573 | 609 | 230 | 142 |
| Protein | Taxonomy | astragaloside a (IC50) | benazepril (IC50) |
|---|---|---|---|
| Angiotensin-converting enzyme | Homo sapiens (human) | 0.0017 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 0.1047 | |
| Angiotensin-converting enzyme | Rattus norvegicus (Norway rat) | 0.0017 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tan, HY; Tang, B; Wei, XQ; Zhang, JG | 1 |
1 other study(ies) available for astragaloside a and benazepril
| Article | Year |
|---|---|
Astragaloside IV inhibits ventricular remodeling and improves fatty acid utilization in rats with chronic heart failure.
Topics: Animals; Benzazepines; Chronic Disease; Chymases; Disease Models, Animal; Energy Metabolism; Fatty Acids; Heart Failure; Heart Ventricles; Humans; Myocardium; Myocytes, Cardiac; PPAR alpha; Rats; RNA, Messenger; Saponins; Triterpenes; Ventricular Remodeling | 2018 |